Shenyang Xingqi Pharmaceutical Co.,Ltd (300573.SZ)
CNY 70.63
(-0.16%)
CNY 70.63
(-0.16%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 357.94 Million CNY | 11.27% |
| 2022 | 315.49 Million CNY | -0.44% |
| 2021 | 323.87 Million CNY | 99.66% |
| 2020 | 157.84 Million CNY | 84.6% |
| 2019 | 84.12 Million CNY | 62.43% |
| 2018 | 50.08 Million CNY | -40.07% |
| 2017 | 86.08 Million CNY | -20.53% |
| 2016 | 109.95 Million CNY | 41.54% |
| 2015 | 71.35 Million CNY | -8.77% |
| 2014 | 58.82 Million CNY | 27.49% |
| 2013 | 63.44 Million CNY | 34.24% |
| 2012 | 50.05 Million CNY | 15.38% |
| 2011 | 43.13 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 39.31 Million CNY | -32.2% |
| 2024 Q2 | 179.03 Million CNY | 217.82% |
| 2024 Q3 | 139.33 Million CNY | -25.35% |
| 2023 Q2 | 72.13 Million CNY | 154.45% |
| 2023 Q1 | 28.35 Million CNY | 1256.9% |
| 2023 FY | - CNY | 11.27% |
| 2023 Q3 | 110.16 Million CNY | 52.71% |
| 2023 Q4 | 80.81 Million CNY | -26.64% |
| 2022 FY | - CNY | -0.44% |
| 2022 Q2 | 54.63 Million CNY | -37.26% |
| 2022 Q1 | 87.07 Million CNY | 62.52% |
| 2022 Q4 | -2.45 Million CNY | -102.44% |
| 2022 Q3 | 100.4 Million CNY | 83.79% |
| 2021 FY | - CNY | 99.66% |
| 2021 Q2 | 60.81 Million CNY | 42.16% |
| 2021 Q3 | 90.97 Million CNY | 49.59% |
| 2021 Q4 | 53.58 Million CNY | -41.1% |
| 2021 Q1 | 42.78 Million CNY | -3.51% |
| 2020 Q4 | 44.33 Million CNY | -13.45% |
| 2020 Q3 | 51.22 Million CNY | 84.13% |
| 2020 FY | - CNY | 84.6% |
| 2020 Q2 | 27.81 Million CNY | 355.16% |
| 2020 Q1 | -10.9 Million CNY | -216.26% |
| 2019 Q4 | 9.37 Million CNY | -66.13% |
| 2019 Q2 | 5.61 Million CNY | 140.25% |
| 2019 Q1 | 2.33 Million CNY | 272.15% |
| 2019 FY | - CNY | 62.43% |
| 2019 Q3 | 27.68 Million CNY | 392.7% |
| 2018 Q3 | 19.37 Million CNY | 4379.65% |
| 2018 FY | - CNY | -40.07% |
| 2018 Q4 | -1.35 Million CNY | -107.01% |
| 2018 Q2 | 432.61 Thousand CNY | 126.92% |
| 2018 Q1 | -1.6 Million CNY | 56.69% |
| 2017 FY | - CNY | -20.53% |
| 2017 Q4 | -3.71 Million CNY | -121.92% |
| 2017 Q2 | 24.44 Million CNY | 101.43% |
| 2017 Q1 | 12.13 Million CNY | -60.02% |
| 2017 Q3 | 16.92 Million CNY | -30.76% |
| 2016 FY | - CNY | 41.54% |
| 2016 Q1 | 11.61 Million CNY | 0.0% |
| 2016 Q2 | 31.77 Million CNY | 173.56% |
| 2016 Q3 | 24.13 Million CNY | -24.03% |
| 2016 Q4 | 30.35 Million CNY | 25.76% |
| 2015 FY | - CNY | -8.77% |
| 2014 FY | - CNY | 27.49% |
| 2014 Q4 | 12.85 Million CNY | 0.0% |
| 2013 FY | - CNY | 34.24% |
| 2012 FY | - CNY | 15.38% |
| 2011 FY | - CNY | 0.0% |